Setmelanotide shows sustained BMI reduction in pediatric hypothalamic obesity after 2.5 years of treatment

Rhythm Pharmaceuticals presented new data showing that pediatric patients with acquired hypothalamic obesity experienced sustained reductions in BMI and BMI-Z scores after 2.5 years of treatment with setmelanotide. The treatment also led to significant improvements in weight categories after one year, with many patients moving to healthier weight classifications. Adverse events were consistent with previous safety profiles, including skin hyperpigmentation and nausea. These findings highlight setmelanotide's potential as a long-term therapy for managing complex pediatric obesity linked to hypothalamic damage.